학술논문
Should high risk smoldering myeloma be treated outside a clinical trial: NO.
Document Type
Article
Author
Source
Subject
*MONOCLONAL gammopathies
*MULTIPLE myeloma
*CLINICAL trials
*SECONDARY primary cancer
*
*
*
Language
ISSN
1042-8194
Abstract
In this issue of Leukemia and Lymphoma, Mohyuddin and colleague examined the characteristics of 32 clinical trials evaluating patients with smoldering multiple myeloma. Since 90% of patients with overt myeloma die of myeloma, I would consider this a justified risk. The inclusion of patients who had active multiple myeloma by today's criteria may explain the very rapid development of CRAB in patients that were randomized to placebo arm in the Spanish trial. [Extracted from the article]